Trending
- Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
- FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
- Immune regulation includes an effector arm: therapeutic implications of phase III IDO/PD-L1 vaccination in melanoma
- Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
- NICE Recommends T-DXd for HER2-Low Metastatic Breast Cancer
- SOHO 2026: Disparities, Efficacy, and Long-Term Safety in B-Cell Lymphoma
- NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
- Mechanisms and disease relevance of DNA break repair pathway choice
Friday, September 18